Literature DB >> 15246639

Differences between patients with a preserved and a depressed left ventricular function: a report from the EuroHeart Failure Survey.

M J Lenzen1, W J M Scholte op Reimer, E Boersma, P J M J Vantrimpont, F Follath, K Swedberg, J Cleland, M Komajda.   

Abstract

AIMS: Due to a lack of clinical trials, scientific evidence regarding the management of patients with chronic heart failure and preserved left ventricular function (PLVF) is scarce. The EuroHeart Failure Survey provided information on the characteristics, treatment and outcomes of patients with PLVF as compared to patients with a left ventricular systolic dysfunction (LVSD). METHODS AND
RESULTS: We performed a secondary analysis using data from the EuroHeart Failure Survey, only including patients with a measurement of LV function (n = 6806). We selected two groups: patients with LVSD (54%) and patients with a PLVF (46%). Patients with a PLVF were, on average, 4 years older and more often women (55% vs. 29%, respectively, p < 0.001) as compared to LVSD patients, and were more likely to have hypertension (59% vs. 50%, p < 0.001) and atrial fibrillation (25% vs. 23%, p = 0.01). PLVF patients received less cardiovascular medication compared to PLVF patients, with the exception of calcium antagonists. Multivariate analysis revealed that LVSD was an independent predictor for mortality, while no differences in treatment effect on mortality between the two groups was observed. A sensitivity analysis, using different thresholds to separate patients with and without LVSD revealed comparable findings.
CONCLUSIONS: In the EuroHeart Failure Survey, a high percentage of heart failure patients had PLVF. Although major clinical differences were seen between the groups, morbidity and mortality was high in both groups.

Entities:  

Mesh:

Year:  2004        PMID: 15246639     DOI: 10.1016/j.ehj.2004.06.006

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  62 in total

1.  Is rhythm-control superior to rate-control in patients with atrial fibrillation and diastolic heart failure?

Authors:  Melissa H Kong; Linda K Shaw; Christopher O'Connor; Robert M Califf; Michael A Blazing; Sana M Al-Khatib
Journal:  Ann Noninvasive Electrocardiol       Date:  2010-07       Impact factor: 1.468

Review 2.  The contribution of observational studies to the knowledge of drug effectiveness in heart failure.

Authors:  Daniela Dobre; Dirk J van Veldhuisen; Mike J L DeJongste; Eric van Sonderen; Olaf H Klungel; Robbert Sanderman; Adelita V Ranchor; Flora M Haaijer-Ruskamp
Journal:  Br J Clin Pharmacol       Date:  2007-08-31       Impact factor: 4.335

Review 3.  Prognostic factors in patients hospitalized for heart failure.

Authors:  Lakshmi Sridharan; Liviu Klein
Journal:  Curr Heart Fail Rep       Date:  2013-12

Review 4.  Update on the Impact of Comorbidities on the Efficacy and Safety of Heart Failure Medications.

Authors:  Christine Chow; Robert J Mentz; Stephen J Greene
Journal:  Curr Heart Fail Rep       Date:  2021-04-09

Review 5.  Epidemiology and importance of renal dysfunction in heart failure patients.

Authors:  Gregory Giamouzis; Andreas P Kalogeropoulos; Javed Butler; Georgios Karayannis; Vasiliki V Georgiopoulou; John Skoularigis; Filippos Triposkiadis
Journal:  Curr Heart Fail Rep       Date:  2013-12

6.  Outcomes in ambulatory chronic systolic and diastolic heart failure: a propensity score analysis.

Authors:  Ali Ahmed; Gilbert J Perry; Jerome L Fleg; Thomas E Love; David C Goff; Dalane W Kitzman
Journal:  Am Heart J       Date:  2006-11       Impact factor: 4.749

7.  Outcome of heart failure with preserved ejection fraction: a multicentre spanish registry.

Authors:  Juan C Castillo; Manuel P Anguita; Manuel Jiménez
Journal:  Curr Cardiol Rev       Date:  2009-11

Review 8.  The heart failure epidemic.

Authors:  Véronique L Roger
Journal:  Int J Environ Res Public Health       Date:  2010-04-19       Impact factor: 3.390

Review 9.  The treatment gap in patients with chronic systolic heart failure: a systematic review of evidence-based prescribing in practice.

Authors:  Ken Lee Chin; Marina Skiba; Andrew Tonkin; Christopher M Reid; Danny Liew; Henry Krum; Ingrid Hopper
Journal:  Heart Fail Rev       Date:  2016-11       Impact factor: 4.214

Review 10.  Vasodilators in the treatment of acute heart failure: what we know, what we don't.

Authors:  Marco Metra; John R Teerlink; Adriaan A Voors; G Michael Felker; Olga Milo-Cotter; Beth Weatherley; Howard Dittrich; Gad Cotter
Journal:  Heart Fail Rev       Date:  2008-12-19       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.